Wells Fargo analyst Larry Biegelsen lowered the firm’s price target on Johnson & Johnson to $152 from $166 and keeps an Equal Weight rating on the shares. J&J’s 2025 sales guidance was about as expected, while margin/EPS guide was better than expected, the firm notes. However, ITCI EPS dilution is worse than Wells expected.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Johnson & Johnson Reports Strong 2024 Financial Results
- Johnson & Johnson Earnings Report: Is it a Beat?
- Needham medtech & diagnostics analyst holds analyst/industry conference call
- Netflix, Seagate, J&J report quarterly beats: Morning Buzz
- Morning Movers: Netflix shares rise following subscriber blowout